Replies to post #45 on Sio Gene Therapies Inc (fka SIOX)

[Inoviorulez]

That's all biotechs. Dilution is the selling of common shares which means the float gets a little bit bigger. It doesn't mean your shares get reduced. So if you buy say 3,000 shares, you still have 3,000 shares after the dilution. The thing is that it adds additional shares into the float. Which if it gets too high makes it harder to go up based on market cap.

IMO with the many catalysts coming up this year and pending all positive the stock will be trading north of $10 per share.

You have first dosing of GM1 patient

Dosing of cohort 2 for PHASE 2 SUNRISE-PD study

2 more readouts for GM2 study

2 more readouts for GM1 study

2 more readouts for SUNRISE-PD study

initiation of OPMD phase 1/2 study

all throughout 2019. There are plenty of catalysts to lift the stock higher throughout the year. Of course, that's pending the data turns out strong.